清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study

医学 药物警戒 医学名词 优势比 回顾性队列研究 观察研究 不良事件报告系统 数据库 重症监护医学 急诊医学 内科学 不利影响 计算机科学
作者
Joe‐Elie Salem,Ali Manouchehri,Melissa Moey,Bénédicte Lebrun‐Vignes,Lisa A. Bastarache,Antoine Pariente,Aurélien Gobert,Jean‐Philippe Spano,Justin Micah Balko,Marc P. Bonaca,Dan M. Roden,Douglas Buckner Johnson,Javid J. Moslehi
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:19 (12): 1579-1589 被引量:1378
标识
DOI:10.1016/s1470-2045(18)30608-9
摘要

Summary

Background

Immune checkpoint inhibitors (ICIs) have substantially improved clinical outcomes in multiple cancer types and are increasingly being used in early disease settings and in combinations of different immunotherapies. However, ICIs can also cause severe or fatal immune-related adverse-events (irAEs). We aimed to identify and characterise cardiovascular irAEs that are significantly associated with ICIs.

Methods

In this observational, retrospective, pharmacovigilance study, we used VigiBase, WHO's global database of individual case safety reports, to compare cardiovascular adverse event reporting in patients who received ICIs (ICI subgroup) with this reporting in the full database. This study included all cardiovascular irAEs classified by group queries according to the Medical Dictionary for Regulatory Activities, between inception on Nov 14, 1967, and Jan 2, 2018. We evaluated the association between ICIs and cardiovascular adverse events using the reporting odds ratio (ROR) and the information component (IC). IC is an indicator value for disproportionate Bayesian reporting that compares observed and expected values to find associations between drugs and adverse events. IC025 is the lower end of the IC 95% credibility interval, and an IC025 value of more than zero is deemed significant. This study is registered with ClinicalTrials.gov, number NCT03387540.

Findings

We identified 31 321 adverse events reported in patients who received ICIs and 16 343 451 adverse events reported in patients treated with any drugs (full database) in VigiBase. Compared with the full database, ICI treatment was associated with higher reporting of myocarditis (5515 reports for the full database vs 122 for ICIs, ROR 11·21 [95% CI 9·36–13·43]; IC025 3·20), pericardial diseases (12 800 vs 95, 3·80 [3·08–4·62]; IC025 1·63), and vasculitis (33 289 vs 82, 1·56 [1·25–1·94]; IC025 0·03), including temporal arteritis (696 vs 18, 12·99 [8·12–20·77]; IC025 2·59) and polymyalgia rheumatica (1709 vs 16, 5·13 [3·13–8·40]; IC025 1·33). Pericardial diseases were reported more often in patients with lung cancer (49 [56%] of 87 patients), whereas myocarditis (42 [41%] of 103 patients) and vasculitis (42 [60%] of 70 patients) were more commonly reported in patients with melanoma (χ2 test for overall subgroup comparison, p<0·0001). Vision was impaired in five (28%) of 18 patients with temporal arteritis. Cardiovascular irAEs were severe in the majority of cases (>80%), with death occurring in 61 (50%) of 122 myocarditis cases, 20 (21%) of 95 pericardial disease cases, and five (6%) of 82 vasculitis cases (χ2 test for overall comparison between pericardial diseases, myocarditis, and vasculitis, p<0·0001).

Interpretation

Treatment with ICIs can lead to severe and disabling inflammatory cardiovascular irAEs soon after commencement of therapy. In addition to life-threatening myocarditis, these toxicities include pericardial diseases and temporal arteritis with a risk of blindness. These events should be considered in patient care and in combination clinical trial designs (ie, combinations of different immunotherapies as well as immunotherapies and chemotherapy).

Funding

The Cancer Institut Thématique Multi-Organisme of the French National Alliance for Life and Health Sciences (AVIESAN) Plan Cancer 2014–2019; US National Cancer Institute, National Institutes of Health; the James C. Bradford Jr. Melanoma Fund; and the Melanoma Research Foundation.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
2秒前
火星上安柏完成签到,获得积分10
4秒前
SHASHA发布了新的文献求助10
6秒前
keyan123完成签到,获得积分10
7秒前
今后的应助被蜗牛好好飞采纳,获得10
8秒前
15秒前
Skywings完成签到,获得积分10
20秒前
20秒前
追梦人2016完成签到 ,获得积分10
22秒前
虚幻烤鸡完成签到,获得积分10
26秒前
超级烨磊完成签到,获得积分10
32秒前
丘比特的应助被下论文好难采纳,获得10
32秒前
简单的冥王星完成签到,获得积分10
48秒前
49秒前
53秒前
王泰一发布了新的文献求助10
54秒前
54秒前
maomao发布了新的文献求助20
1分钟前
ZXD1989完成签到 ,获得积分10
1分钟前
甜美忆寒完成签到,获得积分10
1分钟前
RZH完成签到,获得积分10
1分钟前
1分钟前
1分钟前
1分钟前
欢呼的晓博完成签到,获得积分10
1分钟前
下论文好难完成签到,获得积分10
1分钟前
zhangguo完成签到 ,获得积分10
1分钟前
无极微光的应助被科研通管家采纳,获得20
2分钟前
噼里啪啦完成签到,获得积分10
2分钟前
痴情的不惜完成签到,获得积分10
2分钟前
2分钟前
明理冰海完成签到,获得积分10
2分钟前
luyun发布了新的文献求助10
2分钟前
小铃铛完成签到,获得积分10
2分钟前
Jasper的应助被cc采纳,获得10
2分钟前
2分钟前
2分钟前
小铃铛发布了新的文献求助10
2分钟前
眯眯眼的安雁完成签到 ,获得积分10
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173225
求助须知:如何正确求助?哪些是违规求助? 9565567
关于积分的说明 21780511
捐赠科研通 7767377
什么是DOI,文献DOI怎么找? 3431542
关于科研通互助平台的介绍 2555750
邀请新用户注册赠送积分活动 2476697